|
|
|
> Home > Programs > Conferences & Meetings > Previous Symposia > Cancer Vaccine Collaborative 2002Cancer Vaccine Collaberative 2002
The Cancer Research Institute and the Ludwig Institute for Cancer Research have recently created a new partnership with the objective of developing a collaborative cancer vaccine program involving a number of medical centers initially in New York. To celebrate this, we held a two-day symposium on September 30 and October 1 announcing the launch of the Cancer Vaccine Collaborative and highlighting the major advances of tumor immunology.
About the CVC
Abstracts:
- Robert D. Schreiber, Hiroaki Ikeda, Allen Bruce, Pilar Gil, Gavin Dunn, Kathleen Sheehan, Vijay Shankaran. Washington University, School of Medicine, St. Louis, MO. Lloyd J. Old. Ludwig Institute for Cancer Research, New York, NY. The Three E’s of Cancer Immunoediting.
- Mark J. Smyth. Tumor Immune Surveillance in the Mouse: Effectors and
Regulators. Peter MacCallum Cancer Institute, Victoria, Australia.
- Lewis L. Lanier. Activating NK Cell Receptors Providing Immunity Against Viruses and Tumors. University of California, San Francisco, CA.
- Hiroshi Shiku. Regulatory T Cells in Anti-Tumor Immune Responses. Mie University School of Medicine Mie, Japan.
- Michael Pfreundschuh. Analysis of the B-Cell Repertoire Against Human Cancers. Medizinische Klinik I, Universität des Saarlandes, Homburg, Germany.
- Benoît J. Van den Eynde. Update on Class-I Restricted Tumor Antigens, and Characterization of a Novel Immune Escape Mechanism Based on Tryptophan Catabolism. Ludwig Institute for Cancer Research, Brussels, Belgium.
- Matthew J. Scanlan. Identification and Characterization of Target Molecules for Antigen-Specific Cancer Immunotherapy. Ludwig Institute for Cancer Research, New York, NY.
- Rongfu Wang. Identification of MHC Class II-Restricted Tumor Antigens and Intracellular Delivery of Antigenic Peptides Into Dendritic Cells. Baylor College of Medicine, Houston, TX.
- Achim Jungbluth. Immunophenotyping of Human Tumor Antigens. Ludwig Institute for Cancer Research, New York, NY.
- J.-C. Cerottini. Immunological Monitoring: Lessons From Natural and Vaccine-Induced Responses to Melan-A/MART-1. Ludwig Institute for Cancer Research Lausanne, Switzerland.
- Vincenzo Cerundolo. Prime-Boost Vaccination Strategies With Melanoma Poly-Epitope Constructs. Weatherall Institute of Molecular Medicine, University of Oxford Oxford, United Kingdom.
- Yao-Tseng Chen. Characterization of NY-ESO-1 and SSX Gene Families. Weill Medical College of Cornell University, New York, NY.
- Elke Jäger. Monitoring of Immune Responses Against NY-ESO-1 in Cancer Patients. II. Medizinische Klinik, Krankenhaus Nordwest, Frankfurt, Germany
- Sacha Gnjatic. Comprehensive Approaches to Monitor CD8+ T-Cell Responses Against Tumor Antigen NY-ESO-1. Ludwig Institute for Cancer Research, New York, NY.
- Danila Valmori. Natural and Vaccine-Induced Immune Responses to Cancer-Testis Antigen-Derived Peptides. Ludwig Institute Clinical Trial Center, New York, NY, and Ludwig Institute for Cancer Research, Lausanne, Switzerland.
- Thierry Boon, Vaios Karanikas, Marie Marchand, Nicolas Van Baren, Christophe Lurquin, Pierre Coulie. CTL Responses of Melanoma Patients Vaccinated With a MAGE Antigen. Ludwig Institute
for Cancer Research, Brussels, Belgium, and University of Louvain, Belgium.
- Alexander Knuth. Cancer Vaccine Development in Solid Tumors. II. Medizinische Klinik, Krankenhaus Nordwest, Frankfurt, Germany.
- Jonathan S. Cebon, Ian D Davis, Phillip Parente, Weisan Chen, Mark Shackleton, Wendie Hopkins, Heather Goldie, Eugene Maraskovsky, Qiyuan Chen, Heather Jackson, Tsin Yee Tai. Ludwig Institute for Cancer Research, Heidelberg, Australia. Grant McArthur, Peter MacCallum. Cancer Institute, Melbourne, Australia. Duncan MacGregor, Sue Sturrock. Austin & Repatriation Medical Centre, Heidelberg, Australia, Simon Green, Andrew Cuthbertson, Darryl Maher, David Ryan, Michael McNamara, Debbie Drane, Lena Miloradovic. CSL Limited, Melbourne, Australia. Achim Jungbluth, Gerd Ritter, Elisabeth Stockert, Yao-T. Chen, Eric Hoffman, Sacha Gnjatic, Lloyd Old. Ludwig Institute for Cancer Research, New York, NY. A Phase 1 Clinical Trial of NY-ESO-1 Protein Formulated With Immunostimulatory Complexes (ISCOMÒ Adjuvant) in Patients with Minimal Residual Disease.
- James P. Allison. Mechanisms of Negative Costimulation by CTLA-4 and its Manipulation in Tumor Immunotherapy in Mice and Man. University of California, Berkeley, CA.
- Ira Mellman. Initiating Immunity: Antigen Presentation by Dendritic Cells. Ludwig Institute for Cancer Research, New York, NY and Yale University School of Medicine, New Haven, CT.
- Nina Bhardwaj. Modulation of Immunity by Dendritic Cells. The Rockefeller University and New York University School of Medicine, New York, NY.
- Gerold Schuler. Dendritic Cell-Based Vaccination Against Cancer. University Hospital, of Erlangen, Erlangen, Germany.
- Luisa Lina Villa. Human Papillomavirus Infection: Natural History and Vaccine Development. Ludwig Institute for Cancer Research, Sao Paulo, Brazil.
- Ian H. Frazer1, G.J. Leggatt1, K. Matsumoto1, R. De Kluyver1, M. Quinn2, J. Nicklin3, J. Tan2, L. Perrin3, P. Ng4, V. O’Connor5, O. White1, N. Wendt1, J. Martin1, S.V. Mitchell6, A. McKenzie6, J. Crowley6, S. Edwards6, D. Maher6. 1Centre for Immunologyand Cancer Research, The University of Queensland, Princess Alexandra Hospital, Brisbane, Queensland. 2Royal Women’s Hospital, Parkville, Victoria. 3Royal Women’s Hospital, Brisbane, Queensland. 4Mater Mother’s Hospital, Brisbane, Queensland. 5Queen Elizabeth II Jubilee Hospital, Brisbane, Queensland. 6CSL Limited, Parkville, Victoria, Australia. Immunotherapy for HPV Associated Pre-Cancer.
|
|
|
|